Cocrystal Pharma Files 8-K on Corporate Changes
Ticker: COCP · Form: 8-K · Filed: Jun 28, 2024 · CIK: 1412486
| Field | Detail |
|---|---|
| Company | Cocrystal Pharma, INC. (COCP) |
| Form Type | 8-K |
| Filed Date | Jun 28, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, filing-update, shareholder-vote
Related Tickers: COCP
TL;DR
Cocrystal Pharma (COCP) filed an 8-K on 6/28 for 6/25 events - corporate changes, shareholder votes, and financials.
AI Summary
Cocrystal Pharma, Inc. filed an 8-K on June 28, 2024, reporting on events that occurred on June 25, 2024. The filing indicates changes to its Articles of Incorporation or Bylaws, submission of matters to a vote of security holders, and financial statements and exhibits. The company is incorporated in Delaware and its principal business address is in Bothell, WA.
Why It Matters
This 8-K filing signals potential corporate restructuring or significant shareholder votes, which could impact the company's governance and future direction.
Risk Assessment
Risk Level: medium — Filings related to corporate governance, bylaws, and shareholder votes can indicate significant internal changes or strategic shifts that may carry inherent risks.
Key Players & Entities
- Cocrystal Pharma, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of incorporation
- Bothell, WA (location) — Principal business address
- June 25, 2024 (date) — Earliest event date reported
- June 28, 2024 (date) — Filing date
FAQ
What specific changes were made to Cocrystal Pharma's Articles of Incorporation or Bylaws?
The filing indicates that amendments to Articles of Incorporation or Bylaws were a subject of this report, but the specific details of these amendments are not provided in the excerpt.
What matters were submitted to a vote of security holders?
The filing lists 'Submission of Matters to a Vote of Security Holders' as an item, but the specific matters voted upon are not detailed in the provided text.
What financial statements and exhibits are included in this filing?
The filing notes 'Financial Statements and Exhibits' as an item, but the specific contents are not listed in the excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on June 25, 2024.
What is Cocrystal Pharma's principal business address?
Cocrystal Pharma's principal business address is 19805 N. Creek Parkway, Bothell, WA 98011.
Filing Stats: 1,149 words · 5 min read · ~4 pages · Grade level 13.4 · Accepted 2024-06-28 16:01:23
Filing Documents
- form8-k.htm (8-K) — 62KB
- ex3-1.htm (EX-3.1) — 9KB
- 0001493152-24-025598.txt ( ) — 246KB
- cocp-20240625.xsd (EX-101.SCH) — 3KB
- cocp-20240625_lab.xml (EX-101.LAB) — 33KB
- cocp-20240625_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
executive compensation of every three years
executive compensation of every three years. Item 9.01 Financial Statements and Exhibits. Exhibit No. Description 3.1 Certificate of Amendment to the Certificate of Incorporation of Cocrystal Pharma, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: June 28, 2024 Cocrystal Pharma, Inc. By: /s/ James Martin Name: James Martin Title: Chief Financial Officer and Co-Chief Executive Officer